- CH₣252.66bn
- CH₣285.31bn
- $56.33bn
Novartis gains after raising core profit outlook
Live Markets: Europe before the bell: Positive tone fades
Novartis books $2.2 billion hit from drug trial setbacks, but lifts guidance (updated)
Novartis slightly misses Q3 net sales estimates, but tops core EPS view
Novartis raises full year core operating income guidance
Brief: Novartis Q3 Net Income USD 1,196 Million
Swiss stocks - Factors to watch on October 27
Swiss stocks - Factors to watch on October 27
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Novartis Remibrutinib Delivered Comprehensive Disease Control In Phase III RMS Trials
Bristol Myers discloses patient death in early-stage cell therapy study (updated)
Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows
Novartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Table: Swiss trade surplus at CHF 1.31 bln in September